EP1237583A1 - Near infrared fluorescent contrast agent and fluorescence imaging - Google Patents
Near infrared fluorescent contrast agent and fluorescence imagingInfo
- Publication number
- EP1237583A1 EP1237583A1 EP99965468A EP99965468A EP1237583A1 EP 1237583 A1 EP1237583 A1 EP 1237583A1 EP 99965468 A EP99965468 A EP 99965468A EP 99965468 A EP99965468 A EP 99965468A EP 1237583 A1 EP1237583 A1 EP 1237583A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- contrast agent
- salt
- near infrared
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002872 contrast media Substances 0.000 title claims abstract description 68
- 238000000799 fluorescence microscopy Methods 0.000 title abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 249
- 229910001868 water Inorganic materials 0.000 abstract description 64
- 125000000542 sulfonic acid group Chemical group 0.000 abstract description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 46
- 238000000034 method Methods 0.000 abstract description 22
- 230000005284 excitation Effects 0.000 abstract description 19
- 238000001514 detection method Methods 0.000 abstract description 6
- 230000005540 biological transmission Effects 0.000 abstract description 5
- 230000003902 lesion Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 153
- 239000011734 sodium Substances 0.000 description 98
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 57
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 50
- -1 porphyrin compound Chemical class 0.000 description 50
- 150000003839 salts Chemical class 0.000 description 48
- 125000000217 alkyl group Chemical group 0.000 description 38
- 239000013078 crystal Substances 0.000 description 35
- 159000000000 sodium salts Chemical group 0.000 description 35
- 239000000203 mixture Substances 0.000 description 28
- 238000001914 filtration Methods 0.000 description 22
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 18
- 239000001632 sodium acetate Substances 0.000 description 18
- 235000017281 sodium acetate Nutrition 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 17
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- 229940086542 triethylamine Drugs 0.000 description 16
- 125000000623 heterocyclic group Chemical group 0.000 description 15
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 238000002835 absorbance Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000007706 flame test Methods 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 11
- 238000003384 imaging method Methods 0.000 description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 210000004204 blood vessel Anatomy 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000000862 absorption spectrum Methods 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 125000004964 sulfoalkyl group Chemical group 0.000 description 8
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical class [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 125000005843 halogen group Chemical group 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000002073 fluorescence micrograph Methods 0.000 description 6
- 238000010189 synthetic method Methods 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 5
- 125000005605 benzo group Chemical group 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 5
- 101001053401 Arabidopsis thaliana Acid beta-fructofuranosidase 3, vacuolar Proteins 0.000 description 4
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 4
- 150000003863 ammonium salts Chemical class 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 125000005110 aryl thio group Chemical group 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 101100459319 Arabidopsis thaliana VIII-2 gene Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 238000004163 cytometry Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 238000002428 photodynamic therapy Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- DRORSPJLYCDESA-UHFFFAOYSA-N 4,4-dimethylcyclohexene Chemical group CC1(C)CCC=CC1 DRORSPJLYCDESA-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 101100132433 Arabidopsis thaliana VIII-1 gene Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 150000007524 organic acids Chemical group 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical class C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical class CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- UOXJNGFFPMOZDM-UHFFFAOYSA-N 2-[di(propan-2-yl)amino]ethylsulfanyl-methylphosphinic acid Chemical compound CC(C)N(C(C)C)CCSP(C)(O)=O UOXJNGFFPMOZDM-UHFFFAOYSA-N 0.000 description 1
- OQFSYHWITGFERZ-UHFFFAOYSA-N 2-bromoethanesulfonic acid Chemical compound OS(=O)(=O)CCBr OQFSYHWITGFERZ-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical compound N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 1
- WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical compound C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 description 1
- KFKRXESVMDBTNQ-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-8,13-bis(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C2=C(C)C(C(C)O)=C1C=C(N1)C(C)=C(C(O)C)C1=CC(C(C)=C1CCC(O)=O)=NC1=CC(C(CCC(O)=O)=C1C)=NC1=C2 KFKRXESVMDBTNQ-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
- 229960002078 sevoflurane Drugs 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 125000004436 sodium atom Chemical group 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
Definitions
- the pharmaceutically acceptable salt may be any as long as it forms a nontoxic salt with the compound of the formula [I].
- examples thereof include alkali metal salts such as sodium salt, potassium salt; salt of alkaline earth metal such as magnesium salt, calcium salt and the like; organic ammonium salt such as ammonium salt, triethyl ammonium salt, tributyl ammonium salt, pyridinium salt and the like; salt of amino acid such as lysine salt, arginine salt and the like.
- alkali metal salts such as sodium salt, potassium salt
- salt of alkaline earth metal such as magnesium salt, calcium salt and the like
- organic ammonium salt such as ammonium salt, triethyl ammonium salt, tributyl ammonium salt, pyridinium salt and the like
- salt of amino acid such as lysine salt, arginine salt and the like.
- Particularly preferred is sodium salt causing less toxicity in the living body.
- L 2 , L 3 , L 4 , L 5 , L 6 and L 7 are as defined above and L 8 is an optionally substituted methine group, are reacted in the presence of a base and a solvent to give a compound of the formula [VI-3]
- heterocyclic quaternary salt compound Q3 (3.75 g) were added methanol (25 ml), triethylamine (3.5 ml), dianyl compound A6 (1.95 g) and acetic anhydride (2.4 ml), and the mixture was stirred at room temperature for 1 hour. The insoluble matter was filtered off, and a solution of sodium acetate (3.9 g) in a small amount of methanol was added to the filtrate. The mixture was stirred at room temperature for 1 hour. The resulting crystals were collected by filtration and washed with a small amount of methanol. To the crystals was added water (10 ml) for dissolution.
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP1999/009959 WO2001043781A1 (en) | 1999-12-15 | 1999-12-15 | Near infrared fluorescent contrast agent and fluorescence imaging |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1237583A1 true EP1237583A1 (en) | 2002-09-11 |
Family
ID=8167530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99965468A Withdrawn EP1237583A1 (en) | 1999-12-15 | 1999-12-15 | Near infrared fluorescent contrast agent and fluorescence imaging |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1237583A1 (sh) |
JP (1) | JP2003517025A (sh) |
KR (1) | KR20020082207A (sh) |
CN (1) | CN1217701C (sh) |
AU (1) | AU2097500A (sh) |
BG (1) | BG106822A (sh) |
BR (1) | BR9917587A (sh) |
CA (1) | CA2394539C (sh) |
EA (1) | EA200200635A1 (sh) |
EE (1) | EE200200321A (sh) |
HU (1) | HUP0204024A2 (sh) |
IL (1) | IL149798A0 (sh) |
MX (1) | MXPA02005806A (sh) |
NO (1) | NO328630B1 (sh) |
PL (1) | PL355891A1 (sh) |
SK (1) | SK8142002A3 (sh) |
TR (1) | TR200201567T2 (sh) |
WO (1) | WO2001043781A1 (sh) |
YU (1) | YU44402A (sh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011025950A2 (en) | 2009-08-28 | 2011-03-03 | Visen Medical, Inc. | Systems and methods for tomographic imaging in diffuse media using a hybrid inversion technique |
WO2011038006A1 (en) | 2009-09-22 | 2011-03-31 | Visen Medical, Inc. | Systems and methods for virtual index-matching of diffusive media |
WO2014062716A1 (en) | 2012-10-15 | 2014-04-24 | Visen Medical, Inc. | Systems, methods, and apparatus for imaging of diffuse media featuring cross-modality weighting of fluorescent and bioluminescent sources |
WO2015103420A1 (en) | 2013-12-31 | 2015-07-09 | Memorial Sloan Kettering Cancer Center | Systems, methods, and apparatus for multichannel imaging of fluorescent sources in real time |
WO2016100340A1 (en) | 2014-12-15 | 2016-06-23 | Memorial Sloan Kettering Cancer Center | Cyclic peptides with enhanced nerve-binding selectivity, nanoparticles bound with said cyclic peptides, and use of same for real-time in vivo nerve tissue imaging |
WO2017106525A1 (en) | 2015-12-15 | 2017-06-22 | Memorial Sloan Kettering Cancer Center | Imaging systems and methods for tissue differentiation, e.g., for intraoperative visualization |
WO2018102372A1 (en) | 2016-11-30 | 2018-06-07 | Memorial Sloan Kettering Cancer Center | Inhibitor-functionalized ultrasmall nanoparticles and methods thereof |
EP4015004A1 (en) | 2020-12-18 | 2022-06-22 | Phi Pharma SA | Proteoglycan specific branched peptides |
US11989803B2 (en) | 2018-03-30 | 2024-05-21 | Perkinelmer Health Sciences, Inc. | Systems and methods for 3D reconstruction of anatomical organs and inclusions using short-wave infrared (SWIR) projection tomography |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7682602B2 (en) * | 2003-12-19 | 2010-03-23 | Konica Minolta Medical & Graphic, Inc. | Near-infrared fluorescent contrast medium |
JP2005220045A (ja) * | 2004-02-04 | 2005-08-18 | Konica Minolta Medical & Graphic Inc | 蛍光造影剤 |
JP5074044B2 (ja) * | 2007-01-18 | 2012-11-14 | オリンパス株式会社 | 蛍光観察装置および蛍光観察装置の作動方法 |
WO2009023813A1 (en) * | 2007-08-15 | 2009-02-19 | Applied Soil Water Technologies Llc | Metals recovery from mining heap leach ore |
US20090214436A1 (en) | 2008-02-18 | 2009-08-27 | Washington University | Dichromic fluorescent compounds |
JP2011046663A (ja) | 2009-08-28 | 2011-03-10 | Fujifilm Corp | 近赤外蛍光造影剤 |
WO2011088392A2 (en) * | 2010-01-14 | 2011-07-21 | The Regents Of The University Of California | Devices, systems and methods to detect and reduce or prevent entry of inflammatory mediators into milk ducts |
GB201010878D0 (en) | 2010-06-29 | 2010-08-11 | Ge Healthcare As | Dye compositiion and dye syntheses |
EP3338617B1 (en) | 2012-01-23 | 2020-08-19 | Washington University | Goggle imaging systems and devices |
WO2014149069A1 (en) | 2013-03-15 | 2014-09-25 | Purdue Research Foundation | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
US10806804B2 (en) | 2015-05-06 | 2020-10-20 | Washington University | Compounds having RD targeting motifs and methods of use thereof |
WO2016193396A1 (en) | 2015-06-03 | 2016-12-08 | Surgimab S.A.S. | Fluorescent conjugates |
CN105222828B (zh) * | 2015-09-30 | 2017-05-24 | 东南大学 | 一种贴壁射流速度场和浓度场的同步测量装置与方法 |
US11712482B2 (en) | 2019-12-13 | 2023-08-01 | Washington University | Near infrared fluorescent dyes, formulations and related methods |
CN114459862A (zh) * | 2022-01-13 | 2022-05-10 | 华腾实业(深圳)股份有限公司 | 一种高识别的真菌荧光染色液 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0529002B1 (en) * | 1990-05-15 | 2001-10-04 | Hyperion, Inc. | Fluorescent porphyrin, and fluorescent phthalocyanine - polyethylene glycol, polyol, and saccharide derivatives as fluorescent probes |
ATE264694T1 (de) * | 1995-01-30 | 2004-05-15 | Daiichi Pure Chemicals Co Ltd | Diagnostisches markierungsmittel |
JP2000095758A (ja) * | 1998-09-18 | 2000-04-04 | Schering Ag | 近赤外蛍光造影剤および蛍光造影方法 |
-
1999
- 1999-12-15 BR BR9917587-8A patent/BR9917587A/pt not_active Application Discontinuation
- 1999-12-15 TR TR2002/01567T patent/TR200201567T2/xx unknown
- 1999-12-15 EE EEP200200321A patent/EE200200321A/xx unknown
- 1999-12-15 JP JP2001544917A patent/JP2003517025A/ja active Pending
- 1999-12-15 KR KR1020027007635A patent/KR20020082207A/ko not_active Application Discontinuation
- 1999-12-15 HU HU0204024A patent/HUP0204024A2/hu unknown
- 1999-12-15 EA EA200200635A patent/EA200200635A1/ru unknown
- 1999-12-15 AU AU20975/00A patent/AU2097500A/en not_active Abandoned
- 1999-12-15 EP EP99965468A patent/EP1237583A1/en not_active Withdrawn
- 1999-12-15 MX MXPA02005806A patent/MXPA02005806A/es unknown
- 1999-12-15 WO PCT/EP1999/009959 patent/WO2001043781A1/en not_active Application Discontinuation
- 1999-12-15 CN CN998170437A patent/CN1217701C/zh not_active Expired - Fee Related
- 1999-12-15 CA CA002394539A patent/CA2394539C/en not_active Expired - Fee Related
- 1999-12-15 SK SK814-2002A patent/SK8142002A3/sk unknown
- 1999-12-15 IL IL14979899A patent/IL149798A0/xx not_active IP Right Cessation
- 1999-12-15 PL PL99355891A patent/PL355891A1/xx not_active Application Discontinuation
- 1999-12-15 YU YU44402A patent/YU44402A/sh unknown
-
2002
- 2002-06-13 BG BG106822A patent/BG106822A/bg unknown
- 2002-06-14 NO NO20022837A patent/NO328630B1/no unknown
Non-Patent Citations (1)
Title |
---|
See references of WO0143781A1 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011025950A2 (en) | 2009-08-28 | 2011-03-03 | Visen Medical, Inc. | Systems and methods for tomographic imaging in diffuse media using a hybrid inversion technique |
WO2011038006A1 (en) | 2009-09-22 | 2011-03-31 | Visen Medical, Inc. | Systems and methods for virtual index-matching of diffusive media |
US11903675B2 (en) | 2012-10-15 | 2024-02-20 | Visen Medical, Inc. | Systems, methods, and apparatus for imaging of diffuse media featuring cross-modality weighting of fluorescent and bioluminescent sources |
WO2014062716A1 (en) | 2012-10-15 | 2014-04-24 | Visen Medical, Inc. | Systems, methods, and apparatus for imaging of diffuse media featuring cross-modality weighting of fluorescent and bioluminescent sources |
WO2015103420A1 (en) | 2013-12-31 | 2015-07-09 | Memorial Sloan Kettering Cancer Center | Systems, methods, and apparatus for multichannel imaging of fluorescent sources in real time |
WO2016100340A1 (en) | 2014-12-15 | 2016-06-23 | Memorial Sloan Kettering Cancer Center | Cyclic peptides with enhanced nerve-binding selectivity, nanoparticles bound with said cyclic peptides, and use of same for real-time in vivo nerve tissue imaging |
US10335501B2 (en) | 2014-12-15 | 2019-07-02 | Memorial Sloan Kettering Cancer Center | Cyclic peptides with enhanced nerve-binding selectively, nanoparticles bound with said cyclic peptides, and use of same for real-time in vivo nerve tissue imaging |
US10940216B2 (en) | 2014-12-15 | 2021-03-09 | Cornell University | Cyclic peptides with enhanced nerve-binding selectively, nanoparticles bound with said cyclic peptides, and use of same for real-time in vivo nerve tissue imaging |
WO2017106525A1 (en) | 2015-12-15 | 2017-06-22 | Memorial Sloan Kettering Cancer Center | Imaging systems and methods for tissue differentiation, e.g., for intraoperative visualization |
WO2018102372A1 (en) | 2016-11-30 | 2018-06-07 | Memorial Sloan Kettering Cancer Center | Inhibitor-functionalized ultrasmall nanoparticles and methods thereof |
US11989803B2 (en) | 2018-03-30 | 2024-05-21 | Perkinelmer Health Sciences, Inc. | Systems and methods for 3D reconstruction of anatomical organs and inclusions using short-wave infrared (SWIR) projection tomography |
WO2022129627A1 (en) | 2020-12-18 | 2022-06-23 | Phi Pharma Sa | Oligomeric compounds binding specifically to proteoglycans |
EP4015004A1 (en) | 2020-12-18 | 2022-06-22 | Phi Pharma SA | Proteoglycan specific branched peptides |
Also Published As
Publication number | Publication date |
---|---|
CN1384760A (zh) | 2002-12-11 |
NO328630B1 (no) | 2010-04-12 |
CN1217701C (zh) | 2005-09-07 |
CA2394539C (en) | 2009-10-27 |
IL149798A0 (en) | 2002-11-10 |
YU44402A (sh) | 2005-03-15 |
NO20022837L (no) | 2002-06-14 |
EA200200635A1 (ru) | 2002-12-26 |
JP2003517025A (ja) | 2003-05-20 |
BR9917587A (pt) | 2002-08-06 |
SK8142002A3 (en) | 2002-12-03 |
TR200201567T2 (tr) | 2002-11-21 |
AU2097500A (en) | 2001-06-25 |
CA2394539A1 (en) | 2001-06-21 |
KR20020082207A (ko) | 2002-10-30 |
PL355891A1 (en) | 2004-05-31 |
HUP0204024A2 (en) | 2003-04-28 |
BG106822A (bg) | 2003-01-31 |
EE200200321A (et) | 2003-10-15 |
NO20022837D0 (no) | 2002-06-14 |
WO2001043781A1 (en) | 2001-06-21 |
MXPA02005806A (es) | 2010-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1113822B1 (en) | Near infrared fluorescent contrast agent and fluorescence imaging | |
CA2394539C (en) | Near infrared fluorescent contrast agent and fluorescence imaging | |
US7547721B1 (en) | Near infrared fluorescent contrast agent and fluorescence imaging | |
RU2350355C2 (ru) | Флюоресцентный контрастирующий агент ближней инфракрасной области спектра и способ флуоресцентной томографии | |
CA2413033A1 (en) | Near infrared fluorescent contrast agent and fluorescence imaging | |
US20030180221A1 (en) | Near infrared fluorescent contrast agent and fluorescence imaging | |
JP3507060B2 (ja) | 近赤外蛍光造影剤及び蛍光イメージング | |
NZ525453A (en) | Near infrared fluorescent contrast agent useful for fluorescence imaging of tumour or in angiography | |
CZ2001987A3 (cs) | Fluorescenční kontrastní činidlo vyzařující záření v blízké infračervené oblasti a použití tohoto činidla při fluorescenčním zobrazování | |
CZ20022092A3 (cs) | Fluorescenční kontrastní činidlo vyzařující záření v blízké infračervené oblasti a použití tohoto činidla při fluorescenčním zobrazování | |
JP2005145819A (ja) | 蛍光造影剤および体外蛍光造影方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020531 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 20020531;LT PAYMENT 20020531;LV PAYMENT 20020531;MK PAYMENT 20020531;RO PAYMENT 20020531;SI PAYMENT 20020531 |
|
17Q | First examination report despatched |
Effective date: 20031208 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040420 |